ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)

Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular Rate and Improved Both Symptom Relief and Treatment Satisfaction in AFib-RVR Population